Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 June 2024 | Story Leonie Bolleurs | Photo Kaleidoscope Studios
Prof Hendrik Swart
Prof Hendrik Swart’s prolific publication record, the high impact of his work, and the outstanding quality of his scholarly contributions have placed him among the top 0,05% of all scholars worldwide.

ScholarGPS awarded Prof Hendrik Swart, Senior Professor in the Department of Physics at the University of the Free State (UFS), Highly Ranked Scholar status.

ScholarGPS celebrates Highly Ranked Scholars™ for their performance in various fields, disciplines, and specialties. Prof Swart’s prolific publication record, the high impact of his work, and the outstanding quality of his scholarly contributions have placed him among the top 0,05% of all scholars worldwide.

Prof Swart received Highly Ranked Scholar status (Lifetime) for ranking 16th in the discipline of Phosphor. Highly Ranked Scholars™ – Lifetime refers to distinguished authors, including those who are currently active, retired, or deceased. These scholars are recognised for their exceptional lifetime scholarly contributions, placing them in the top 0,05% of all scholars. Their achievements are evaluated across four categories: overall (across all fields), within their specific field of study, within their particular discipline, and across all specialties they are associated with.

Additionally, Prof Swart received Highly Ranked Scholar status (prior five years) for ranking first in Condensed Matter Physics, 42nd in Physics, 155th in Sensor, 207th in Physical Science and Mathematics, and 969th in all fields.

Scientific profile and credibility

ScholarGPS is a California-based company that applies artificial intelligence, data mining, machine learning, and other data science techniques to its massive database of more than 200 million publications and 3 billion citations to rank more than 30 million scholars and 55 000 institutions worldwide. They categorise more than 200 million scholarly publications into specific academic specialties. These specialties are further organised into 177 disciplines and 14 overarching fields. As a result of this extensive classification effort, scholars who are considered highly ranked within their respective fields can now be identified with greater precision. This identification is done not only within each academic specialty, but also across disciplines and fields, providing a comprehensive view of scholarly achievement and expertise. This system allows for the identification of top scholars within various areas of academic research in a way that was not possible before.

Prof Swart, who is an NRF B1-rated researcher, currently also holds the SARChI Research Chair: Solid-state Luminescent and Advanced Materials (2023-2027). On receiving this award from ScholarGPS, he says it is always a privilege to be recognised as one of the top scholars in your specific field, especially at this late stage of his career.

Professionally, Prof Swart says this award may boost his scientific profile and credibility in the academic community, potentially leading to more collaborations and partnerships.

In the field of condensed matter physics, the impact of his work is specifically noteworthy in the study of defects and impurities within semiconductors, along with their practical applications in optoelectronic devices. Moreover, his significant contributions extend to understanding optical and electronic properties at the nanoscale, bearing implications for the development of semiconductor technology, including light-emitting diodes (LEDs), photovoltaic cells, and quantum dots.

Primarily focused on mentorship

He believes his successes in physics and advances in understanding the universe are the result of a combination of variables, including innovative research, collaboration and networking, mentorship, effective communication, persistence, and resilience. “I am primarily focused on mentorship, which is critical to developing the next generation of physicists and creating a supportive environment for learning and discovery, as well as conducting groundbreaking research and making novel discoveries that are critical to pushing the boundaries of physics. I am always searching for opportunities to collaborate with other scholars, both inside and outside my discipline, which will result in constructive exchange of ideas, interdisciplinary discoveries, and collective problem solving.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept